FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC

In our exclusive interview, Dr. Ramalingam, who is also a professor in the Department of Hematology and Medical Oncology and the Roberto C. Goizueta Distinguished Chair for Cancer Research at Emory University School of Medicine, shed light on key findings from the CheckMate-227 trial. He also discussed the impact of the approval on other frontline treatment regimens in the metastatic setting and highlighted ongoing research with immunotherapy in the field.